Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
March 2014—Enzo Life Sciences’ Histamine ELISA kit provides a quantitative detection method for measuring histamine in human, rat, mouse, and canine samples. Because of histamine’s potent role in the immune response, it is present in a transitory state in the body and can only be measured within minutes of release. The half-life of histamine in a biological system is four minutes before its conversion to n-methyl histamine.
September 2014—Ohaus will launch in September its Adventurer line of analytical and precision balances for standard laboratory weighing. Adventurer has nine application modes, including weighing, percent weighing, counting, check weighing, dynamic weighing, totalization, formulation, density determination, and display hold.
September 2014—EKF Diagnostics highlighted its expanding product portfolio at its subsidiary’s booth, Stanbio Laboratory. DiaSpect Tm, which previewed at the meeting, is a palm-sized hemoglobin measurement system that gives laboratory-quality performance for anemia screening. Delivering results in one to two seconds, this analyzer is CE marked and currently undergoing FDA approval.
February 2014—Streck’s A1c-Cellular, a whole red blood cell A1c control with intact red blood cells, is now assayed for the Abbott Architect Integrated ci Systems. A1c-Cellular tests the entire HbA1c procedure, including the lysing of the red blood cell.
February 2014—Protagen has entered into a long-term collaboration agreement with Qiagen to target the development of novel protein-based companion diagnostics for autoimmune disorders. Under the terms of the agreement, Qiagen will gain access to Protagen’s proprietary SeroTag technology platform, which enables the discovery and validation of novel protein-based marker panels.
February 2014—Title21 Health Solutions released its Cellular Therapy Solution, which enables cellular therapy environments, transplant centers, and cord blood banks to achieve traceability, enhance quality controls, and streamline the life cycle of therapeutic products in an easy-to-use platform.
February 2014—Chembio Diagnostics has entered a follow-on, milestone-based development agreement with a private contracting organization acting on behalf of the Centers for Disease Control and Prevention for a multiplex POC influenza immunity test using Chembio’s patented Dual Path Platform technology.
February 2014—Nikon Instruments announced a strategic partnership between Nikon and Jeol to research and develop tools that can correlate light and electron microscopy data to further push the limits of resolution.
February 2014—Meridian Life Science offers several products suitable for the development of an ELISA detection assay for Ebola. The new Ebola reagents are C01762M MAb to Ebola virus, C86037M MAb to Ebola virus, C86180M MAb to Ebola virus, R01577 Ebola Zaire Nucleoprotein (E. coli) recombinant, and R01578 Ebola Sudan Nucleoprotein (E. coli) recombinant.
February 2014—EKF Diagnostics has entered a multiyear collaborative relationship with Joslin Diabetes Center in support of the ongoing clinical and commercial translation of tumor necrosis factor receptor 1 and 2 biomarkers. EKF will access certain clinical and research expertise at Joslin under the center’s corporate liaison program to further develop its TNFR biomarker test.
